Merck’s Suvorexant To Face FDA Panel Scrutiny On Next-Day Driving Effects

The Peripheral and Central Nervous System Drugs Advisory Committee’s May 22 review of the first-in-class insomnia drug will include data from two studies assessing the compound’s residual effects on next-day driving.